Prognostic value of the expression of p53, bcl-2, and bax oncoproteins, and neovascularization in patients with radically resected non-small-cell lung cancer.
作者： R M Apolinario , P van der Valk , J S de Jong , W Deville , J van Ark-Otte
DOI: 10.1200/JCO.1997.15.6.2456
关键词:
摘要: PURPOSETo assess the prognostic value of p53, bcl-2, bax, and neovascularization in radically resected non-small-cell lung cancer (NSCLC) patients.PATIENTS AND METHODSTumors from 116 patients were assessed by immunohistochemistry for expression p53 (DO7 PAb1081), quantification microvessel density (CD-31). In addition, bax was 61 stage I tumors. The median levels each marker used as cutoff points.RESULTSp53 not correlated to any patient or tumor characteristic, whereas bcl-2 showed higher squamous cell carcinomas (P < .001). significantly related with male sex = .006) adenocarcinoma type .0013). status, one monoclonal antibody (MoAb), predictive survival; however, combination staining results obtained two MoAbs identified DO7-/PAb1801+ tumors those worst prognosis. associated longer survival stag...
elsevier.com
sci-hub.se 参考文章(43)
Maryla Krajewska, Ahmed Shabaik, Stanislaw Krajewski, Hong Gang Wang, John C. Reed, Toshiyuki Miyashita, Immunohistochemical determination of in vivo distribution of Bax, a dominant inhibitor of Bcl-2. American Journal of Pathology. ,vol. 145, pp. 1323- 1336 ,(1994)
G. Krystal, J. M. Ben-Ezra, M. M. Grimes, M. J. Kornstein, Small cell carcinomas of the lung express the Bcl-2 protein. American Journal of Pathology. ,vol. 145, pp. 1036- 1040 ,(1994)
T Mitsudomi, Seth M Steinberg, Marion M Nau, David Carbone, Domenico D'Amico, Sara Bodner, Herbert K Oie, R Ilona Linnoila, James L Mulshine, John D Minna, None, p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features. Oncogene. ,vol. 7, pp. 171- 180 ,(1992)
Gazzeri S, Brambilla E, Brambilla C, Moro D, Caron de Fromentel C, Jacrot M, Gouyer, Immunohistochemical study of p53 in human lung carcinomas. American Journal of Pathology. ,vol. 143, pp. 199- 210 ,(1993)
Silvia Sabbioni, Maria Monne, Carlo M. Croce, Massimo Negrini, Subrata Haldar, Down-Regulation of bcl-2 by p53 in Breast Cancer Cells Cancer Research. ,vol. 54, pp. 2095- 2097 ,(1994)
Steinberg Sm, Mulshine Jl, Linnoila Ri, Ebina M, Relationship of p53 Overexpression and Up-Regulation of Proliferating Cell Nuclear Antigen with the Clinical Course of Non-Small Cell Lung Cancer Cancer Research. ,vol. 54, pp. 2496- 2503 ,(1994)
Risto Bloigu, Raija Sormunen, Pekka Rainio, Anna-Kaisa Eerola, Ylermi Soini, Kirsi Vähäkangas, Veli-Pekka Lehto, Paavo Pääkkö, Ulla Törmänen, Enhanced Apoptosis Predicts Shortened Survival in Non-Small Cell Lung Carcinoma' Cancer Research. ,vol. 55, pp. 5595- 5602 ,(1995)
L Pylkkänen, S Toikkanen, H Joensuu, Bcl-2 protein expression and long-term survival in breast cancer. American Journal of Pathology. ,vol. 145, pp. 1191- 1198 ,(1994)
J S Lee, A Yoon, S K Kalapurakal, J Y Ro, J J Lee, N Tu, W N Hittelman, W K Hong, Expression of p53 oncoprotein in non-small-cell lung cancer: a favorable prognostic factor. Journal of Clinical Oncology. ,vol. 13, pp. 1893- 1903 ,(1995) , 10.1200/JCO.1995.13.8.1893
P Verderio, O Caffo, C Doglioni, P Bevilacqua, M Barbareschi, L Morelli, P Boracchi, G Gasparini, P D Palma, F A Mauri, Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer. Clinical Cancer Research. ,vol. 1, pp. 189- 198 ,(1995)